February 29, 2024
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
Global NASH Council Chair Zobair Younossi joins the Surfers to discuss his recent review article on MASLD epidemiology and what stakeholders can do to help stem the tsunami of new patients.
This conversation reviews several other topics related to the new MASLD nomenclature: impact on NITs and ICD codes, future vision for MASH, and general satisfaction with the process to date.
This conversation focuses on ways the new MASLD Nomenclature can improve the ways providers explain MASH to patients.
This conversation on the new MASLD nomenclature rollout has two major elements: discussing the role of Allied Health Providers and looking more broadly at the ongoing rollout process.
In this discussion, Jeff Lazarus, who oversaw the global Delphi process that led to the final new MASLD nomenclature, describe how a Delphi process works and some of its strengths and weaknesses here.
In this discussion, Maru Rinella, who co-led the new MASLD nomenclature process, and Jeff Lazarus, who oversaw a large Delphi process that led to the final result, describe how the process came to be.
Maru Rinella, Jeff Lazarus and Meena Bansal, all key players in the new MASLD nomenclature process join patient advocate Mike Betel, Louise Campbell and Roger Green to discuss the process, the benefits of the outcome, and where things go from here.